Novavax shares Q1 2026 financial results
They highlight progress on corporate growth strategy and invite to a live call at 8:30 a.m. ET.
See the latest news and media coverage for Novavax. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing vaccines
novavax.comLast updated
In short: Novavax reported stronger-than-expected Q1 2026 earnings as it pivoted from vaccine sales toward high-value technology licensing agreements.
They highlight progress on corporate growth strategy and invite to a live call at 8:30 a.m. ET.
Total revenue is $140 million. Announces Pfizer Matrix-M license and multiple MTAs. Reiterates 2026 revenue framework of $230-270 million.
Interview with Jonathan Fix summarizes safety from 66 trials, showing mild reactogenicity and positive benefit-risk profile across populations.
They share key operational highlights. Registration is available.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Shares of Novavax (NVAX) fell 2.84% to $8.38 in the afternoon trade on Tuesday, adding to a six-session slide. The stock has fallen around 18...
The FDA has granted full approval to Novavax's COVID-19 vaccine after a delay, but has limited its use to older adults and people aged 12...
・Novavax posted Q1 revenue of $139.5 million, above analysts' estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received...
Track Novavax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novavax and other trending companies.